Notable Labs, Ltd.

Notable Labs, Ltd. is a clinical-stage platform therapeutics company that develops predictive medicines for cancer patients. Its proprietary Predictive Medicines Platform (PMP) bio-simulates a patient's cancer treatment to predict clinical response and enable fast-track therapeutic development. The lead product is Volasertib, a polo-like kinase 1 inhibitor that induces cell cycle arrest and apoptosis in cancer cells. The company is also developing two candidate predictive medicines and clinical-stage candidates for platform-predicted responders with acute myeloid leukemia. Based in Foster City, California, Notable Labs filed a voluntary petition for liquidation under Chapter 7 on October 13, 2024, in the U.S. Bankruptcy Court for the District of Delaware.